Wire · opportunities
PD-1/VEGF Bispecific Antibody Receives FDA Fast Track Designation in NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA granted fast track designation to cesalatamig, a PD-1/VEGF bispecific antibody by OncoC4, for treating non–small cell lung cancer (NSCLC) that has progressed after PD-(L)1 immunotherapy and platinum-based chemotherapy. This supports expedited development and phase 3 trials in the US and China.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Sep 2026 and 17 Sep 2026.
◆ ◆ The Wire takeaway
You can accelerate plans in immuno-oncology by factoring in FDA fast track to shorten cesalatamig's market entry. For biotech founders, this clearance signals a clearer pathway to speed clinical development in refractory lung cancer.
◆ Coverage
2 sources · first reported 16 Sep 2026 · latest 17 Sep 2026
◆ Related on Wire
◆ Topics